Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2.1 Patients with HER2-low status may now be eligible for HER2-targeted treatment, which could significantly improve their outcome.2 The VENTANA HER2 (4B5) test is the only approved companion…